Shanxi Zhendong Pharmaceutical (SHE:300158) — Market Cap & Net Worth
Market Cap & Net Worth: Shanxi Zhendong Pharmaceutical (300158)
Shanxi Zhendong Pharmaceutical (SHE:300158) has a market capitalization of $721.67 Million (CN¥4.93 Billion) as of August 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #10249 globally and #2689 in its home market, demonstrating a 5.74% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanxi Zhendong Pharmaceutical's stock price CN¥4.97 by its total outstanding shares 992303056 (992.30 Million). See how much does Shanxi Zhendong Pharmaceutical reinvest in capital to understand how much of operating cash flow is reinvested back into capital assets.
Shanxi Zhendong Pharmaceutical Market Cap History: 2015 to 2026
Shanxi Zhendong Pharmaceutical's market capitalization history from 2015 to 2026. Data shows change from $1.04 Billion to $721.67 Million (-2.58% CAGR).
Shanxi Zhendong Pharmaceutical Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanxi Zhendong Pharmaceutical's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.21x
Shanxi Zhendong Pharmaceutical's market cap is 0.21 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $1.04 Billion | $2.26 Billion | $64.65 Million | 0.46x | 16.06x |
| 2016 | $1.04 Billion | $3.28 Billion | $203.06 Million | 0.32x | 5.12x |
| 2017 | $734.98 Million | $3.73 Billion | $301.54 Million | 0.20x | 2.44x |
| 2018 | $407.18 Million | $3.42 Billion | -$147.44 Million | 0.12x | N/A |
| 2019 | $517.28 Million | $4.40 Billion | $142.76 Million | 0.12x | 3.62x |
| 2020 | $593.03 Million | $4.85 Billion | $262.03 Million | 0.12x | 2.26x |
| 2021 | $905.59 Million | $5.09 Billion | $2.62 Billion | 0.18x | 0.35x |
| 2022 | $1.08 Billion | $3.73 Billion | -$51.29 Million | 0.29x | N/A |
| 2023 | $980.13 Million | $3.63 Billion | -$43.98 Million | 0.27x | N/A |
| 2024 | $627.29 Million | $2.97 Billion | -$1.33 Billion | 0.21x | N/A |
Competitor Companies of 300158 by Market Capitalization
Companies near Shanxi Zhendong Pharmaceutical in the global market cap rankings as of August 5, 2026.
Key companies related to Shanxi Zhendong Pharmaceutical by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #504 globally with a market cap of $52.60 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #543 globally with a market cap of $49.47 Billion USD ( CN¥338.09 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #549 globally with a market cap of $48.78 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #504 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #543 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $49.47 Billion | CN¥53.00 |
| #549 | GALDERMA GROUP AG | NYSE:GALDY | $48.78 Billion | $42.97 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €14.70 |
Shanxi Zhendong Pharmaceutical Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanxi Zhendong Pharmaceutical's market cap moved from $1.04 Billion to $ 721.67 Million, with a yearly change of -2.58%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥721.67 Million | -14.46% |
| 2025 | CN¥843.64 Million | +34.49% |
| 2024 | CN¥627.29 Million | -36.00% |
| 2023 | CN¥980.13 Million | -9.40% |
| 2022 | CN¥1.08 Billion | +19.46% |
| 2021 | CN¥905.59 Million | +52.70% |
| 2020 | CN¥593.03 Million | +14.64% |
| 2019 | CN¥517.28 Million | +27.04% |
| 2018 | CN¥407.18 Million | -44.60% |
| 2017 | CN¥734.98 Million | -29.31% |
| 2016 | CN¥1.04 Billion | +0.14% |
| 2015 | CN¥1.04 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 4th, 2026 the market cap of Shanxi Zhendong Pharmaceutical was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $721.67 Million USD |
| MoneyControl | $721.67 Million USD |
| MarketWatch | $721.67 Million USD |
| marketcap.company | $721.67 Million USD |
| Reuters | $721.67 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shanxi Zhendong Pharmaceutical
Shanxi Zhendong Pharmaceutical Co.,Ltd, together with its subsidiaries, engages in the research, development, production, and sales of pharmaceutical drugs in China. It offers drugs for various fields, including tumors, dermatology, digestion, urology, and cardio-cerebral drugs. The company also provides Chinese herbal medicines. Shanxi Zhendong Pharmaceutical Co.,Ltd was founded in 1995 and is b… Read more